Literature DB >> 6319393

Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase.

S S Pan, P A Andrews, C J Glover, N R Bachur.   

Abstract

Under anaerobic conditions and with proper electron donors, NADPH-cytochrome P-450 reductase (EC 1.6.2.4) and xanthine oxidase (EC 1.2.3.2) similarly reductively metabolized mitomycin C. Reversed phase high performance liquid chromatography was used to separate, detect, and isolate several metabolites. Three metabolites were identified by mass spectrometry and thin layer chromatography as 1,2-cis- and trans-2,7-diamino-1-hydroxymitosene and 2,7-diaminomitosene. Three metabolites were phosphate-dependent, and two of them were identified to be 1,2-cis- and trans-2,7-diaminomitosene 1-phosphate. The amounts of the five identified metabolites generated during the reduction of mitomycin C varied with pH and nucleophile concentration. At pH 6.5, 2,7-diaminomitosene was essentially the only metabolite formed, whereas from pH 6.8 to 8.0, trans- and cis-2,7-diamino-1-hydroxymitosene increased in quantity as 2,7-diaminomitosene decreased. The disappearance of mitomycin C and the production of metabolites were enzyme and mitomycin C concentration-dependent. Substrate saturation was not reached for either enzyme up to 5 mM mitomycin C. Electron paramagnetic resonance studies demonstrated the formation of mitomycin C radical anion as an intermediate during enzymatic activation. Our results indicate that either enzyme catalyzed the initial activation of mitomycin C to a radical anion intermediate. Subsequent spontaneous reactions, including the elimination of methanol and the opening of the aziridine ring, generate one active center at C-1 which facilitates nucleophilic attack. Simultaneous generation of two reactive centers was not observed. All five primary metabolites were metabolized further by either flavoenzyme. The secondary metabolites exhibited similar changes in their absorbance spectra and were unlike the primary metabolites, suggesting that a second alkylating center other than C-1 was generated during secondary activation. We propose that secondary activation of monofunctionally bound mitomycin C is probably a main route for the bifunctional binding of mitomycin C to macromolecules and that the cytotoxic actions of mitomycin C result from multiple metabolic activations and reactions.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6319393

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  Porfiromycin disposition in oxygen-modulated P388 cells.

Authors:  S S Pan
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Modulation of cytotoxic but not genotoxic effects by dicumarol on mitomycin C treated Chinese hamster cells.

Authors:  D Fratta; G Rainaldi; A Piras; A Moretti; T Mariani; L Vatteroni; S Simi; P G Gervasi
Journal:  Cytotechnology       Date:  1991-02       Impact factor: 2.058

3.  Distinct roles of cytochrome P450 reductase in mitomycin C redox cycling and cytotoxicity.

Authors:  Yun Wang; Joshua P Gray; Vladimir Mishin; Diane E Heck; Debra L Laskin; Jeffrey D Laskin
Journal:  Mol Cancer Ther       Date:  2010-05-25       Impact factor: 6.261

Review 4.  Enzymology of bioreductive drug activation.

Authors:  D Ross; H D Beall; D Siegel; R D Traver; D L Gustafson
Journal:  Br J Cancer Suppl       Date:  1996-07

Review 5.  Mitomycinoid alkaloids: mechanism of action, biosynthesis, total syntheses, and synthetic approaches.

Authors:  Phillip D Bass; Daniel A Gubler; Ted C Judd; Robert M Williams
Journal:  Chem Rev       Date:  2013-05-08       Impact factor: 60.622

6.  Phyllanthus emblica Linn. fruit extract potentiates the anticancer efficacy of mitomycin C and cisplatin and reduces their genotoxicity to normal cells in vitro.

Authors:  Xi-Han Guo; Juan Ni; Jing-Lun Xue; Xu Wang
Journal:  J Zhejiang Univ Sci B       Date:  2017 Dec.       Impact factor: 3.066

Review 7.  Cellular pharmacology of quinone bioreductive alkylating agents.

Authors:  S Rockwell; A C Sartorelli; M Tomasz; K A Kennedy
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

Review 8.  Are reduced quinones necessarily involved in the antitumour activity of quinone drugs?

Authors:  J Butler; B M Hoey
Journal:  Br J Cancer Suppl       Date:  1987-06

9.  Pharmacokinetics and toxicity of mitomycin C in rodents, given alone, in combination, or after induction of microsomal drug metabolism.

Authors:  S Kerpel-Fronius; J Verwey; M Stuurman; B Kanyár; P Lelieveld; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

10.  Mitomycin C is not metabolized by but is an inhibitor of human kidney NAD(P)H: (quinone-acceptor)oxidoreductase.

Authors:  J J Schlager; G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.